Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M736Revenue $M31.3Net Margin (%)-781.0Z-Score-5.0
Enterprise Value $M806EPS $-1.3Operating Margin %-640.5F-Score1
P/E(ttm))0Cash Flow Per Share $0.7Pre-tax Margin (%)-781.3Higher ROA y-yN
Price/Book10.110-y EBITDA Growth Rate %0Quick Ratio4.2Cash flow > EarningsY
Price/Sales26.55-y EBITDA Growth Rate %0Current Ratio4.2Lower Leverage y-yN
Price/Cash Flow6.3y-y EBITDA Growth Rate %0ROA % (ttm)-48.6Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-369.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M195ROI % (ttm)-57.3Gross Margin Increase y-yN

Gurus Latest Trades with EXEL

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
EXELJean-Marie Eveillard 2014-03-31 Reduce-0.01%$3.38 - $8.24
($6.84)
$ 3.59-48%Reduce -65.91%400,000
EXELJohn Burbank 2013-03-31 Sold Out -0.0019%$4.41 - $5.03
($4.69)
$ 3.59-24%Sold Out0
EXELJohn Burbank 2012-12-31 Buy $4.33 - $5.32
($4.79)
$ 3.59-25%New holding, 10753 sh.10,753
EXELJean-Marie Eveillard 2012-09-30 Add0.02%$4.28 - $6.45
($5.29)
$ 3.59-32%Add 422.58%1,175,800
EXELJean-Marie Eveillard 2012-03-31 Add$4.49 - $6.47
($5.14)
$ 3.59-30%Add 125%225,000
EXELJean-Marie Eveillard 2011-12-31 Buy $3.95 - $7.81
($5.01)
$ 3.59-28%New holding, 100000 sh.100,000
EXELCarl Icahn 2011-09-30 Sold Out -0.43%$5.5 - $9.22
($7.34)
$ 3.59-51%Sold Out0
EXELJean-Marie Eveillard 2011-03-31 Sold Out $7.22 - $12.45
($9.89)
$ 3.59-64%Sold Out0
EXELJean-Marie Eveillard 2010-12-31 Buy 0.01%$3.98 - $9.08
($5.66)
$ 3.59-37%New holding, 280000 sh.280,000
EXELJean-Marie Eveillard 2009-12-31 Sold Out -0.02%$5.33 - $8
($6.86)
$ 3.59-48%Sold Out0
EXELJean-Marie Eveillard 2009-09-30 Buy 0.02%$4.4 - $6.99
($5.65)
$ 3.59-36%New holding, 274700 sh.274,700
EXELJean-Marie Eveillard 2009-06-30 Sold Out -0.01%$4.16 - $5.55
($4.88)
$ 3.59-26%Sold Out0
EXELJean-Marie Eveillard 2009-03-31 Reduce$4.32 - $5.85
($4.8)
$ 3.59-25%Reduce -25.67%144,800
EXELCarl Icahn 2008-12-31 Add0.19%$2.4 - $5.12
($3.8)
$ 3.59-6%Add 80.31%2,357,110
EXELJean-Marie Eveillard 2008-12-31 Add$2.4 - $5.12
($3.8)
$ 3.59-6%Add 25.84%194,800
EXELCarl Icahn 2008-09-30 Buy 0.18%$4.8 - $7.12
($6.1)
$ 3.59-41%New holding, 1307280 sh.1,307,280
EXELJean-Marie Eveillard 2008-09-30 Reduce$4.8 - $7.12
($6.1)
$ 3.59-41%Reduce -44.12%154,800
EXELJean-Marie Eveillard 2008-06-30 Add0.01%$5.07 - $7.93
($6.7)
$ 3.59-46%Add 151.82%277,000
EXELGeorge Soros 2008-06-30 Sold Out $5.07 - $7.93
($6.7)
$ 3.59-46%Sold Out0
EXELJean-Marie Eveillard 2008-03-31 Add$5.79 - $8.32
($6.8)
$ 3.59-47%Add 37.5%110,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

EXEL is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
EXEL Jean-Marie Eveillard 2014-03-31400,0000.210-65.91%
Premium Most recent portfolio changes are included for Premium Members only!


EXEL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
WILLSEY LANCEDirector 2013-08-29Buy10,000$5.15-30.29view
MARCHESI VINCENT TDirector 2012-12-20Buy4,000$4.68-23.29view
MARCHESI VINCENT TDirector 2012-12-19Buy6,000$4.72-23.94view
Schwab GiselaEVP and Chief Medical Officer 2012-12-10Buy25,000$4.39-18.22view
MARCHESI VINCENT TDirector 2012-06-14Sell7,000$5.13-30.02view
RIVERA LUPE MEVP, Operations 2010-12-17Sell29,427$8.5-57.76view
RIVERA LUPE MEVP, Operations 2010-12-15Sell75,000$7.5-52.13view
Schwab GiselaEVP & Chief Medical Officer 2010-12-09Sell4,112$6.5-44.77view
WILLSEY LANCEDirector 2010-09-07Buy36,200$3.6-0.28view
WILLSEY LANCEDirector 2010-08-30Buy71,300$3.1812.89view

Press Releases about EXEL :

Quarterly/Annual Reports about EXEL:

News about EXEL:

Articles On GuruFocus.com
Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 
Exelixis Inc. (EXEL) CFO Frank Karbe buys 16,500 Shares Aug 25 2010 
Exelixis Inc. Reports Operating Results (10-Q) Aug 05 2010 
Exelixis Inc. Reports Operating Results (10-Q) May 11 2010 
Exelixis Announces Second Quarter 2009 Financial Results Jul 30 2009 
Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs Dec 12 2008 

More From Other Websites
Most active Nasdaq-traded stocks Jul 22 2014
EXELIXIS, INC. Files SEC form 8-K, Other Events Jul 17 2014
Exelixis to Release Second Quarter 2014 Financial Results on Thursday, July 31, 2014 Jul 16 2014
Exelixis to Release Second Quarter 2014 Financial Results on Thursday, July 31, 2014 Jul 16 2014
Exelixis (EXEL) Showing Signs Of A Dead Cat Bounce Today Jul 16 2014
Biotechs, social stocks weak after Yellen warning Jul 15 2014
Exelixis (EXEL) Is Today's Perilous Reversal Stock Jul 15 2014
Exelixis (EXEL) Soars: Stock Adds 23% in Session Jul 15 2014
Roche Presents Encouraging Data on Cobimetinib Jul 14 2014
Why the Exelixis Cancer Trial News Matters This Time Jul 14 2014
Why Exelixis (EXEL) Stock Is SpikingToday Jul 14 2014
Exelixis Sees Success in Melanoma Treatment With Drug Combination Jul 14 2014
Exelixis seen as potential target for Roche, TheStreet says Jul 14 2014
Investor Believes Roche Buys Exelixis for Skin-Cancer Drug Jul 14 2014
Roche, Exelixis Skin Cancer Drug Delays Tumor Progression Jul 14 2014

Add Notes, Comments or Ask Questions

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide